Breaking News, Promotions & Moves

Pharming Group Appoints CSO

Calias responsible for ERT programs and driving scientific and strategic direction

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dr. Perry Calias has been appointed chief scientific officer at Pharming Group NV. Dr. Calias will have overall responsibility for the company’s new Enzyme Replacement Therapy (ERT) programs, driving scientific milestones, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.   With the recent acquisition of TRM SASU, Pharming is expanding its validated platform for the production of recombinant human proteins, an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters